Relinde I Y Lieverse (Relinde Iy Lieverse)

Years Active: 2020-2021
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Veronica Olivo Pimentel, Damiënne Marcus, Alexander Ma van der Wiel, Natasja G Lieuwes, Rianne Biemans, Relinde I Y Lieverse, Dario Neri, Jan Theys, Ala Yaromina, Ludwig J Dubois, Philippe Lambin
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. Journal for immunotherapy of cancer 9 (3) (2021)
Relinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, Esther G C Troost, Sine R Hadrup, Anne-Marie C Dingemans, Lizza E L Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J Dubois, Philippe Lambin
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC cancer 20 (1) (2020)
Relinde I Y Lieverse, Damiënne Marcus, Alexander M A van der Wiel, Evert J Van Limbergen, Jan Theys, Ala Yaromina, Philippe Lambin, Ludwig J Dubois
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Molecular oncology 14 (7) (2020)

Relinde I Y Lieverse.css-eqlu8i{font-size:small;padding-left:4px;} (Relinde Iy Lieverse)